This is an important issue. In our work to model inflammatory bowel disease, we are looking for signature cytokine and biomarker and permeability responses compared against those that are clinically validated for inflammatory bowel disease (IBD). In addition, we further validate against the ability of our model to capture effects and MOA of established clinically relevant IBD.
